Search Results

hand, a course of ipilimumab for treating metastatic malignant melanoma costs about $120,000. If I had metastatic malignant melanoma and this drug worked for me, I would live longer. But I might have complications from the drug, and I would still

utilizing language for non-professional audiences. The NCCN Guidelines for Patients can be accessed at NCCN.com . Highlights of the NCCN 17th Annual Conference Include Presentations on Lung Cancer Screening, Melanoma, and Non-Hodgkin’s Lymphomas

is ipilumumab, an mAb-targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), previously shown to improve survival in metastatic melanoma. 5 Combining ipilumumab with nivolumab (targeting programmed death [PD]-1) improved the response rate

Background: Lymphedema is a form of soft tissue swelling from interstitial accumulation of fluid due to disruption of the lymphatic system. In melanoma patients, the incidence of lymphedema ranges from 5-10% in upper extremity and 28-40% in lower

of price disclosure of surgical procedures for five cancers (Breast, Lung, Melanoma, Colon, and Prostate) among hospitals ranked by the American College of Surgeon’s Commission on Cancer (CoC). Methods : We identified non-federal, adult, and non

Background : The value of sentinel lymph node (SLN) surgery for patients with clinically node-negative T1b through T3 cutaneous melanomas is well-established. However, further precision in selecting patients for SLN surgery would be desirable as

Use of small molecule inhibitors specific to activating BRAF V600 mutations first demonstrated efficacy in metastatic melanoma. 1 Recently, similar results were observed in patients with BRAF -mutated non–small cell lung cancer, leading to FDA

leads to cell proliferation and survival. BRAF V600E is the most common mutation, although there are others that occur less frequently (V600K/D/R). BRAF-specific inhibitors have been developed and are effective in melanoma, with approximately 50% of

.org ). Evaluation of the Primary Tumor In many ways, MCC is analogous to thick melanoma: most lesions are thick and deeply invasive, regional nodal metastases are commonly identified, and subclinical distant dissemination is present in many patients at diagnosis

(formerly known as PLX-4032) has achieved high response rates and increased overall survival in patients with V600E BRAF–mutated melanoma. 7 The experience in colorectal tumors with V600E BRAF mutations has revealed only minimal activity for this agent